Treatment options for CML include BCR–ABL tyrosine kinase inhibitors (TKIs), interferon alpha, chemotherapy, stem cell transplantation, or clinical trials of novel therapies (Baccarani et al. 2013; NCCN v4. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.